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Ventricular tachycardia induced by programmed elec•
trical stimulation during amiodarone therapy often does 
not preclude a good clinical response. The purpose of 
this study was to determine whether use of discriminant 
analysis could distinguish patients who remained asymp•
tomatic from those who subsequently developed symp•
tomatic ventricular tachycardia or cardiac arrest. Stud•
ies were performed in 37 patients with sustained 
ventricular tachycardia who still had ventricular tachy•
cardia induced during programmed electrical stimula•
tion during amiodarone therapy. The mean follow-up 
time was 14.1 ± 1.3 months (±SEM). Twenty-three 
patients remained asymptomatic, whereas 14 patients 
had symptomatic recurrence of their ventricular 
tachycardia. 
In patients with recurrence of arrhythmia compared 
with asymptomatic patients, administration of amioda•
rone caused a longer ventricular effective refractory pe•
riod (296 ± 8 versus 271 ± 7 ms, p < 0.05) and a 
greater change in corrected QT [QTcJ interval (90 ± 18 
versus 44 ± 9 ms, p < 0.02), but no difference in the 
decrease in premature ventricular complexes after treat-
Serial electrophysiologic testing is a sensitive and specific 
method for predicting clinical response to some antiar•
rhythmic drugs in patients with recurrent sustained ventric-
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ment with amiodarone. During amiodarone therapy, 
non bundle branch reentrant repetitive ventricular re•
sponses were induced by a single ventricular extrastim•
ulus during sinus rhythm in 9 of 14 patients with re•
current arrhythmias compared with 2 of 21 asymptomatic 
patients (p = 0.001). Also, less aggressive pacing tech•
niques were required to induce ventricular tachycardia 
in 9 of 14 symptomatic patients compared with 4 of 23 
asymptomatic patients (p < 0.02). A discriminant anal•
ysis using the presence of non bundle branch reentrant 
repetitive ventricular responses, change in method of 
ventricular tachycardia induction and either the change 
in QT c interval or ventricular effective refractory period 
correctly identified clinical outcome in 90 % of the pa•
tients, and all patients with recurrent arrhythmias were 
classified correctly. It is concluded that electrophysio•
logic testing during amiodarone therapy can provide data 
that identify patients who appear to be at risk for de•
velopment of ventricular tachycardia after hospital 
discharge. 
(J Am Coil CardioI1985;6:814-21) 
ular tachycardia (1,2). However, we (3) and other inves•
tigators (4,5) have reported that many patients may remain 
asymptomatic during amiodarone therapy despite induction 
of ventricular tachycardia during serial electrophysiologic 
testing with this agent. It has therefore been suggested that 
high risk patients be treated with amiodarone empirically 
without the aid of invasive testing (6,7). Such a recom•
mendation fails to consider that factors other than the ini•
tiation of ventricular tachycardia may be useful to determine 
the clinical outcome of patients taking amiodarone. The 
purpose of this study was to investigate the hypothesis that 
combinations of electrophysiologic variables are useful to 
identify patients who appear at increased risk for recurrence 
of symptomatic ventricular tachycardia or sudden death dur•
ing amiodarone therapy. 
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Methods 
Study patients. The study group comprised 37 patients, 
including 28 men and 9 women aged 55 ± 3 years (mean ± 
SEM). Twenty-six had coronary artery disease demonstrated 
by a documented myocardial infarction or cineangiographic 
presence of 75% or greater stenosis of one or more coronary 
arteries, or both. Entry criteria included recurrence of sus•
tained ventricular tachycardia despite treatment with con•
ventional agents and often two to three investigational anti•
arrhythmic drugs, induction of ventricular tachycardia during 
a drug-free control electrophysiologic study and ventricular 
tachycardia still induced at repeat electrophysiologic study 
14 to 21 days after initiation of amiodarone therapy (800 
mg/day). Although several months of amiodarone therapy 
are needed to achieve steady state conditions, it is not fea•
sible to keep patients in the hospital for this length of time 
before repeating electrophysiologic studies. Thus, electro•
physiologic testing was performed after 2 to 3 weeks of 
amiodarone therapy to investigate the hypothesis that data 
obtained at this time would identify patients most susceptible 
to recurrence of arrhythmias. Two additional patients had 
no ventricular tachycardia induced during amiodarone ther•
apy and were excluded from further analysis. 
Study protocol. All patients were admitted to a telem•
etry unit where their cardiac rhythm was monitored contin•
uously. A 24 hour ambulatory electrocardiographic record•
ing and an exercise test were performed in the control state 
before electrophysiologic testing if the patient's rhythm was 
stable, and 24 to 48 hours before the scheduled repeat elec•
trophysiologic study while the patient received amiodarone. 
If ventricular tachycardia was noted on either test during 
amiodarone treatment, a second antiarrhythmic agent was 
added to amiodarone and the noninvasive tests were re•
peated. Seventeen patients received amiodarone and another 
antiarrhythmic agent. These drugs included encainide (n = 
5), aprindine (n = 5), mexiletine (n = 2), disopyramide 
(n = 2), procainamide (n = 2) and quinidine (n = I). 
Electrophysiologic testing during amiodarone therapy was 
performed when no ventricular tachycardia was demon•
strated on noninvasive testing. Thirty-five patients had a 
repeat 24 hour electrocardiographic recording performed 
before electrophysiologic drug study. Of these 35 patients, 
18 were receiving therapy with amiodarone alone and 17 
were taking amiodarone in addition to a second antiar•
rhythmic agent. Two patients taking amiodarone alone did 
not have a 24 hour electrocardiographic recording before 
repeat electrophysiologic study. 
Long-term electrocardiographic recording. A contin•
uous 24 hour ambulatory electrocardiographic recording was 
performed in 35 of 37 patients before the final electro•
physiologic drug study. In 16 of these 35 patients a contin•
uous electrocardiographic recording was performed before 
and after 12 to 15 days of single drug therapy with amio-
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darone. In all patients a 24 hour printout of the electrocar•
diogram (7700 Eliminator, American Edwards Laborato•
ries) was obtained and the number of premature ventricular 
complexes was counted manually by the authors. Sections 
of each record were printed out at 25 mmls paper speed to 
verify the ventricular origin of the wide QRS complexes. 
Pacing protocol. The pacing protocol to induce ven•
tricular tachycardia has been reported previously in detail 
(2). Briefly, single and double premature ventricular stimuli 
were induced during sinus rhythm and at ventricular pacing 
cycle lengths of 600, 500 and 400 ms, scanning diastole to 
the point of ventricular refractoriness. Burst right ventricular 
pacing of three to eight complexes at cycle lengths of 250 
ms or more was also performed. If ventricular tachycardia 
was not induced at the right ventricular apex, the stimulation 
protocol was repeated at the right ventricular outflow tract. 
An arbitrary hierachy of pacing techniques (Fig. I) was 
defined to determine whether a more or less aggressive 
pacing technique was needed to induce ventricular tachy•
cardia during amiodarone therapy. In general, a complete 
pacing protocol was performed at both ventricular sites un•
less sustained ventricular tachycardia was reproducibly in•
duced before completion of the protocol. 
Long-term amiodarone dosage. All patients were dis•
charged receiving 800 mg/day of amiodarone. This dosage 
was decreased to 600 mg/day after 1 to 4 months of treat•
ment, and then to 400 mg/day after 4 to 8 months. Plasma 
levels of amiodarone were not available during this study. 
Follow-up. Patients were followed up in the arrhythmia 
clinic and seen 1 month after discharge and every 3 months 
thereafter. They were questioned in detail about potential 
drug side effects and recurrence of symptoms. Outpatient 
24 hour continuous electrocardiographic recordings were 
performed routinely 6 months after discharge, or if war•
ranted by symptoms suggestive of recurrent arrhythmia. 
Definitions. Nonbundle branch reentrant repetitive ven•
tricular response (8) is defined as a second ventricular com•
plex not due to bundle branch reentry that follows an induced 
premature ventricular complex initiated during sinus rhythm. 
Inducible ventricular tachycardia (8) is defined as three 
or more consecutive nonbundle branch reentrant repetitive 
ventricular responses. 
Figure 1. Hierarchy of ventricular stimulation techniques used to 
initiate ventricular tachycardia. Burst = 3 to 8 ventricular com•
plexes at cycle lengths of 250 ms or more; RV 2 = I ventricular 
extrastimulus introduced during sinus rhythm; RV 2 V 3 = 2 ven•
tricular extrastimuli introduced during sinus rhythm; V I V 2 = 1 
ventricular extrastimulus introduced during ventricular pacing; 
V I V 2 V 3 = 2 ventricular extrastimuli introduced during ventricular 
pacing. 
"More" Aggressive Pacing Technique ~ 
RV. RV,V. V,V, V,V,V, Burst 
~ "Less" Aggressive Pacing Technique 
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Sustained ventricular tachycardia (2) is defined as ven•
tricular tachycardia lasting 30 seconds or more or requiring 
termination before 30 seconds because of hemodynamic 
compromise. 
Nonsustained veniricu~ar tachycardia (2) is defined as 
ventricular tachycardia of three beats to less than 30 seconds 
in duration. 
Statistical analysis. Comparisons between symptomatic 
and asymptomatic patients were made using t tests for con•
tinuous variables. Categorical variables were analyzed using 
the chi-square test for contingency tables. Fisher's exact test 
was used for 2 x 2 tables (9). Multivariate analysis to 
determine the set of variables that best predicted outcome 
was performed using stepwise discriminant analysis and the 
Cox proportional hazards linear model (10,11). The Mann•
Whitney U test was used to analyze premature ventricular 
complex counts before and during drug therapy because the 
counts do not have a Gaussian distribution. 
Results 
Patient characteristics (Table 1). Twenty-three treated 
patients (asymptomatic group) had neither recurrence of 
symptoms suggestive of ventricular tachycardia nor any ven•
tricular tachycardia recorded during outpatient 24 hour am•
bulatory continuous electrocardiographic recordings pet•
formed every 3 to 6 months. Fourteen treated patients 
(symptomatic group) had symptomatic events after hospital 
discharge; sustained ventricular tachycardia occurred in 11 
and sudden death in 3 patients (Fig. 2). There was no sta•
tistical difference between symptomatic and asymptomatic 
patients in age, sex, history of cardiac arrest, presence of 
coronary artery disease, presence of left ventricular aneu•
rysm or an abnormal «50%) ejection fraction (Table 1). 
Similarly, there was no difference between groups ih either 
the number of patients who received an antiarrhythmic agent 
Table 1. Patient Characteristics (mean ± SEM) 
Asymptomatic Symptomatic 
(n = 23) (n = 14) P Value 
Age (yr) 53 ± 3 57 ± 3 NS 
Sex NS 
Men 16 12 
Women 7 2 
Etiologic diagnosis NS 
CAD 15 11 
Non-CAD 8 3 
Ejection fraction NS 
Normal 6 
Abnormal 17 13 
LV aneurysm 12 10 NS 
History of cardiac arrest 15 13 NS 
CAD = coronary artery disease; LV = left ventricular; NS = not 
significant; p = probability value; SEM = standard error of the mean. 
VT INDUCED 
23/~14 
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Figure 2. Follow-up data on 39 patients receiving amiodarone 
therapy for ventricular tachycardia (VT). SD = sudden death; 
VT-S = sustained ventricular tachycardia. 
in addition to amiodarone or in the mean amiodarone dosage 
at follow-up. 
Comparison of nlUltiple electrophysiologic vari•
ables-control study (table 2). Before drug treatment there 
was no statistically significant difference between sympto•
matic and asymptomatic patients in spontaneous sinus cycle 
length, HV interval, corrected QT interval (12) or ventric•
ular effective and functional refractory periods. The mean 
cycle length of the inducible ventricular tachycardia was 
longer in the symptomatic group (p = 0.03), as was the 
value for the ventricular tachycardia cycle length minus the 
ventricular effective refractory period (p = 0.04). 
Comparison of multiple electrophysiologic vari•
ables-amiodarone study (Table 3). During the electro•
physiologic study while the patients received amiodarone 
there was no statistically significant difference between 
symptomatic and asymptomatic groups in the spontaneous 
sinus cycle length, HV interval, corrected QT interval or 
the value for ventricular tachycardia cycle length minus the 
ventricular effective refractory period. Both the ventricular 
effective refractory period (p = 0.04) and the mean ven•
tricular tachycardia cycle length were no longer in the symp•
tomatic group. Nonbundle branch reentrant repetitive ven•
tricular response (8) was induced during sinus rhythm with 
Table 2. Electrophysiologic Variables: Control Study (mean ± 
SEM) 
Asymptomatic Symptomatic 
Variable (ms) (n = 23) (n = 14) P Value 
SCL 790 ± 33 813 ± 48 NS 
HV 52 ± 3 55 ± 3 NS 
QTc 421 ± 8 406 ± 16 NS 
VERP 242 ± 5 255 ± 6 NS 
VFRP 270 ± 7 282 ± 6 NS 
VTCL 276 ± 18 337 ± 19 0.03 
VT CL - VERP 25 ± 14 77 ± 20 0.04 
CL = cycle length; HV = HV interval; QTc = corrected QTc interval; 
SCL = spontaneous sinus cycle length; VERP = ventricular effective 
refractory period; VFRP = ventricular functional refractory period; VT 
= ventricular tachycardia; other abbreviations as in Table I. 
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Table 3. Electrophysiologic Variables: Amiodarone Study 
(mean ± SEM) 
Asymptomatic Symptomatic 
Variable (ms) (n = 23) (n = 14) P Value 
SCL 866 ± 34 888 ± 33 NS 
HV 62 ± 3 70 ± 3 NS 
QTc 464 ± 10 499 ± 21 NS 
VERP 271 ± 7 296 ± 8 0.04 
VFRP 302 ± 9 333 ± II 0.06 
VTCL 354 ± 20 420 ± 25 0.05 
VT CL - VERP 69 ± 15 114 ± 22 NS 
RVR + 2121 9/14 0.001 
RVR + = positive repetitive ventricular response; other abbreviations 
as in Tables I and 2. 
a single ventricular extrastimulus more frequently in the 
symptomatic than in the asymptomatic group (p = 0.001). 
Change in electrophysiologic variables during ther•
apy (Table 4). In comparing the control study with the 
study in which the patient received amiodarone, there was 
no significant difference between the symptomatic and 
asymptomatic groups in the change in sinus cycle length, 
HV interval, ventricular effective refractory period or ven•
tricular tachycardia cycle length. However, the change in 
the QTc interval was greater in the symptomatic than in the 
asymptomatic group (p = 0.02). In addition, four patients 
in the group with recurrent ventricular tachycardia devel•
oped new non bundle branch reentrant repetitive ventricular 
response in contrast to no patient in the asymptomatic group. 
During the control and amiodarone studies, there was no 
difference between the asymptomatic 'and symptomatic groups 
in the duration of ventricular tachycardia induced by pro•
grammed ventricular stimulation. 
Method of ventricular tachycardia induction (Fig. 
3). Although there was no difference between the asymp•
tomatic and symptomatic groups in the method of induction 
of ventricular tachycardia during the control study, a dif•
ference between groups (p = 0.014) was evident during 
Table 4. Change in Electrophysiologic Variables: Control Study 
Versus Amiodarone Study (mean ± SEM) 
Asymptomatic Symptomatic 
Variable (ms) (n = 23) (n = 14) P Value 
a SCL 75 ± 27 65 ± 64 NS 
aHV II ± 3 16 ± 4 NS 
a QTc 44 ± 9 90 ± 18 0.02 
a VERP 29 ± 6 42 ± 12 NS 
a VFRP 32 ± 8 51 ± 13 NS 
a VTCL 78 ± 13 83 ± 28 NS 
aRVR 0.03 
Negative to positive 0 4 
Same 18 7 
Positive to negative 3 2 
Abbreviations as in Tables I, 2 and 3. 
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testing after amioda".Ji!'·· 
techniques were cap,lbk 
in 9 of 14 patients 
with only 4 of 23 as~· ,):. 
is that ventricular tad).: 
.' '. Less aggressive pacing 
liHh. ing ventricular tachycardia 
'vLlptomatic group, compared 
; 'i) tients. Of particular note 
.\,: induced with one or two 
extra stimuli introdU'.cd ',li'US rhythm in six symp-
tomatic patients but . '1, I \ ,Y it: :hymptomatic patient. 
Continuous electn; .. 'l'I,tt.ogj·;)O}t;1c recording. Thirty-five 
patients had 24 hour " lc,ri':hll" dectrocardiographic re•
cordings during drug. \ h". L hospital discharge. The 
24 hour median prep',· :.,ilar complex count was 
200 (range 0 to 2,591 i .(\ :", ;,,:~,,",)tomatic group (n = 22) 
and 907 (range 0 to 5. ·k ·ymptomatic group (n = 
13) (p = NS). Sixteel' ; I ':::1t symptomatic and eight 
asymptomatic, had ,',mtinuous electrocardio-
graphic recording bek drug therapy with amio-
darone (Fig. 4). For; ,he 24 hour median pre-
mature ventricular COL ,t was 1,390 (range 13 to 
20,790) before therapy '1. : "nificantly decreased to 116 
(range 0 to 5,346) during all )Jarone treatment (p < 0.004). 
There was no significant difference between symptomatic 
and asymptomatic patients in premature ventricular complex 
counts either at control Of drug study. Further, amiodarone 
caused a 90% reduction in premature ventricular complex 
counts in six of eight asymptomatic patients and four of 
eight symptomatic patients (p = NS). 
Follow-up (Fig. 2). All patients were followed up for 
a mean of 14.1 ± 1.3 n,.mths. Twenty-three patients have 
remained asymptomatic nean follow-up time 17.5 ± 1.5 
months) and 14 have hd symptomatic recurrence of ar•
rhythmia at a mean follow-up time of 8.5 ± 1.6 months. 
In the symptomatic group, three patients with a prior history 
of cardiac arrest died suddenly and eight have required car•
dioversion for recurrence of sustained ventricular tachycar•
dia. Eleven of the 14 arrhythmia recurrences occurred within 
4 months of hospital discharge. 
Discriminant analysis (Tables 5 and 6). Several vari•
ables were significantly different in asymptomatic and 
symptomatic groups (Tables 2 to 4). However, substantial 
overlap occurred between groups and no clear break was 
evident to separate asymptomatic from symptomatic pa•
tients. Thus, stepwise discriminant anaylsis was performed 
to determine which con ~. ination of variables led to an in•
creased risk of recurren',:';. Because variables that are not 
significantly related to recurrence alone could be signifi•
cantly related in combination with other variables, all vari•
ables previously discussed were included in the analysis. 
Discriminant analysis requires that subjects included in 
the analysis have values for all variables to be considered. 
Because the change in ventricular effective refractory period 
after drug therapy appeared to be an important predictor and 
was only available in 25 patients, two parallel analyses were 
done. Both involved all other available measurements but 
only one included change in ventricular effective refractory 
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PATIENTS SYMPTOMATIC DURING FOLLOW-UP (N-14) PATIENTS ASYMPTOMATIC DURING FOLLOW-UP (N = 23) 
CONTROL AMIODARONE 
~ 
RV. 
Z!RV. 
z 
0 / RV.V. 
2 
1 
2 V,V. >V,V. 
3 
11 V, V. V. 4_V,V,V, 
o BURST. • BURST 
period. Initial stepwise discriminant analyses included the 
large set of variables. A final analysis was done with the 
two best sets of variables to allow inclusion of as many 
subjects as possible in developing the discriminant functions. 
The set of variables leading to increased risk of 
arrythmia recurrence comprised conversion from negative 
to positive repetitive ventricular response, increases in QTc 
interval or ventricular effective refractory period with drug 
therapy and easier induction of ventricular tachycardia dur•
ing drug therapy. A large increase in ventricular effective 
refractory period in combination with the other two factors 
was associated with an increased risk of symptomatic re•
currence. The significance levels in Tables 5 and 6 indicate 
the importance of the variable in the discriminant analysis 
and not its significance in a univariate analysis. 
Cox proportional hazards linear model was fitted to de•
termine which combination of all the variables led to in•
creased risk of recurrence under the assumptions of this 
model. The stepwise Cox regression procedure selected as 
risk indicators the same three variables-change in QTc 
interval or ventricular effective refractory period, change in 
repetitive ventricular response status and change in method 
of ventricular tachycardia induction-selected by the dis•
criminant analysis. Again, increases in the QTc interval or 
ventricular effective refractory period, change of repetitive 
ventricular response from negative to positive with drug 
therapy and easier method of ventricular tachycardia in•
duction with drug therapy were associated with increased 
risk of recurrence of ventricular tachycardia or cardiac arrest. 
Figure 5 displays in a simple format the riskfor recurrent 
events for combinations of the three variables used in the 
discriminant function. If changes from control to drug study 
in QT interval or ventricular effective refractory period ex•
ceed the values shown, ventricular tachycardia is more likely 
to recur. The patient with the best chance of remaining 
asymptomatic during amiodarone therapy would have the 
values located in the top of the middle column of Figure 5: 
~ 
4 
2 
4 
4 
0 
CONTROL AMIODARONE 
~ ~ 
RV. /RV. 
1 
0 • RV.V. 0 
1 
7 V,V. 2~V1V' 8 
3 
14 v,V.V. 1~~V1V.V3 13 
1 
1 BURST. ~~BURST 3 
Figure 3. Pacing technique used to initiate ventricular tachycardia 
in the two patient groups before (control) and during amiodarone 
therapy. N = number of patients; other abbreviations as in Fig•
ure 1. 
repetitive ventricular response status changing from positive 
to negative and ventricular tachycardia during therapy be•
coming harder to induce, that is, requiring a more aggressive 
pacing technique. This patient would need a change in QT 
Figure 4. Ability of amiodarone therapy to suppress premature 
ventricular complexes. 
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Table 5. Discriminant Analysis (RVR, .:l QTc and .:l induction method) 
Actual Group (n = 31) 
Asymptomatic 20 
Symptomatic II 
Classification accuracy = 90.3% (28 of 31) 
Asymptomatic 
17 
o 
Assigned Group 
Symptomatic 
3 
II 
Risk Factors Structure Coefficient* p Value 
~ QTc 
RVR 
~ Ind method 
RVR - to + + I 
RVR same = 0 
RVR + to - = -I 
0.35 
0.54 
0.49 
Ind easier = + I 
Ind same = 0 
Ind harder = - I 
<0.001 
0.003 
<0.001 
*Structure coefficient gives correlation of variable with discriminant function. A positive value means that 
larger values of the variable are associated with symptomatic follow-up. Critical value = 0.332 (midpoint of 
group centroids). Values greater than or equal to critical value predict recurrence; discriminant function = 
-0.878 + 1.949 (RVR) + 1.l30 (Ind) - 0.011 (~QTc). Ind = pacing technique to induce ventricular 
tachycardia; ~ QTc = QTc (drug) - QTc (control); RVR = repetitive ventricular response. 
interval or ventricular effective refractory period greater 
than 390 or 240 ms, respectively, to be at risk for recurrence 
of symptoms, A patient likely to have recurrence of symp•
toms would have values located in the lower left comer of 
Figure 5: repetitive ventricular response status changing from 
negative to positive and ventricular tachycardia easier to 
induce; this patient has a high probability of having recurrent 
ventricular tachycardia regardless of the change in QTc in•
terval or ventricular effective refractory period, 
Discussion 
Discriminant analysis. The most important new obser•
vation in this study is that use of multiple variables obtained 
during serial electrophysiologic testing can accurately clas•
sify clinical outcome in patients receiving amiodarone in 
whom ventricular tachycardia is induced during pro-
grammed ventricular stimulation, Previous investigations 
(13-15) suggested that whereas noninduction of ventricular 
tachycardia during programmed ventricular stimulation pre•
dicts a favorable clinical outcome, induction of ventricular 
tachycardia does not yield accurate predictive data regarding 
clinical efficacy of amiodarone treatment (3-5,7), However, 
the latter studies used only induction of ventricular tachy•
cardia as an end point to predict patients likely to have 
recurrent arrhythmias, on the basis of earlier investigations 
showing that failure to prevent ventricular tachycardia ini•
tiation during conventional drug therapy augured a high 
probability of spontaneous recurrence of ventricular tachy•
cardia or sudden death (16,17), This latter approach does 
not appear to be useful for amiodarone therapy, 
Change in repetitive ventricular response status, The 
variables used in the discriminant analysis were change in 
repetitive ventricular response status, change in mode of 
Table 6. Discriminant Analysis (RVR, .:l VERP and .:l induction method) 
Actual Group (n = 25) 
Asymptomatic 18 
Symptomatic 7 
Classification accuracy = 92.0% (23 of 25) 
Risk Factors 
~ VERP 
RVR 
~ Ind method 
RVR - to + + 1 
RVR same = 0 
RVR + to - = -I 
Asymptomatic 
16 
o 
Structure Coefficient 
0.16 
0.58 
0.42 
Ind easier = + I 
Ind same = 0 
Ind harder = - I 
Assigned Group 
Symptomatic 
2 
7 
p Value 
<0.001 
0.005 
<0.001 
Critical value = 0.523. Discriminant function = -0.645 + 2.182 (RVR) + 1.449 (Ind) - 0.020 
(~ VERP). ~ VERP = ventricular effective refractory period (drug) - ventricular effective refractory period 
(control); other abbreviations as in previous tables. 
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CHANGE IN RVR STATUS 
:z Neg to Pos Pos to Neg Same 
0 
i= A aTc > 26 ms A aTc > 390 ms A aTe> 213 ms 
(J Harder 
~ 
0 A VERI' > 22 m. A VERI' > 240 m. A VERP > 131 ms 
:!: f--. 
I-
> Same 
u.. 
0 
A aTe 2 0 A aTe> 267 ms A aTe> 110 ms 
I 
AVERP~O A VERP > 167 ms A VERP > 58 ms 
0 
0 Easier :J: 
I-
w 
2 
A aTe 2 0 A aTe> 184 ms A aTe 2 0 
I 
AVERP> 0 A VERP > 95 ms AVERP>O 
Figure 5. Risk of recurrent events for patients who have ventric•
ular tachycardia (VT) induced during amiodarone therapy. Ven•
tricular tachycardia is more likely to recur if the constellation of 
conditions in anyone of the boxes is met. It is less likely to recur 
if they are not met. Either .l QTc or .l VERP may be utilized. 
Predictive accuracy is greater than 90% in our patients . .l QTc = 
QTc (control study) - QTc (drug study); .l VERP = ventricular 
effective refractory period (VERP) (control study) - VERP (drug 
study). Change in repetitive ventricular response (RVR) status and 
comparison of ventricular tachycardia induction method are in the 
direction of control to drug study. 
ventricular tachycardia induction and change in either QT 
interval or ventricular effective refractory period. The in•
duction of repetitive ventricular responses by ventricular 
extrastimuli introduced during sinus rhythm is not sensitive 
enough to be clinically useful by itself (8). This was also 
true in the present study, but we found that data on repetitive 
ventricular response status were useful if combined with 
other variables, as suggested previously (8). Thus, in pa•
tients who have ventricular tachycardia initiated during 
amiodarone therapy, a change in repetitive ventricular re•
sponse induction from positive to negative suggests a fa•
vorable outcome, but a change from negative to positive 
suggests an unfavorable outcome (Fig. 5). 
Change in mode of induction. The second major variable 
in the discriminant function equation is change in pacing 
technique used to initiate ventricular tachycardia. The hi•
erarchy of aggressiveness of pacing mode to induce ven•
tricular tachycardia (Fig. 1) is arbitrary, as judged by our 
experience and the results of other investigators (18,19). 
Commonly, two extrastimuli delivered during ventricular 
pacing (V 1 V 2 V 3) are necessary to initiate ventricular tachy•
cardia at control study (19), and this technique was nec•
essary to induce ventricular tachycardia in 25 of the 37 
patients. Ventricular extrastimuli introduced during sinus 
rhythm (RV2' RV2V3) do not commonly induce ventricular 
tachycardia, and only 2 of 37 patients had ventricular tachy•
cardia initiated with this pacing mode before drug therapy. 
During amiodarone therapy the RV 2 or RV 2 V 3 pacing tech•
nique induced ventricular tachycardia in 6 of 14 sympto•
matic patients but in only 1 of 23 asymptomatic patients 
(Fig. 3). Because most of the former patients also changed 
from a negative to a positive repetitive ventricular response, 
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they represent a classification with a high probability of 
recurrence of symptoms (Fig. 5). 
One potential problem with the hierarchy of pacing tech•
niques is presenting burst pacing as the most aggressive 
technique. Because we now believe that burst pacing has 
poor reproducibility, we use instead three extrastimuli if 
ventricular tachycardia is not initiated by one or two ex•
trastimuli. However, burst pacing added little to the data in 
this study, because only one patient required this technique 
to initiate ventricular tachycardia before drug therapy (Fig. 
3). 
Spontaneous arrhythmia suppression. We evaluated 
whether premature ventricular complex suppression alone 
or in combination with other variables was useful to predict 
drug success or failure. Our data differ from those of Na•
demanee et al. (7), who evaluated premature ventricular 
complex suppression between 2 and 8 weeks of amiodarone 
therapy. We were unable to demonstrate usefulness of pre•
mature ventricular complex suppression after 2 weeks of 
therapy as a univariate or multivariate variable to classify 
patients likely to be symptomatic or asymptomatic. In fact, 
amiodarone caused a greater than 90% decrease in premature 
ventricular complex counts per 24 hours in equal numbers 
of symptomatic and asymptomatic patients. It should be 
noted that these conclusions are made on the basis of a 
relatively small sample size, and sampling of a larger patient 
population may yield different results. 
Timing of electrophysiologic testing during amioda•
rone therapy. The half-life of amiodarone is approximately 
1 month (20), and it could be argued that electrophysiologic 
testing should have been performed after more than 14 days 
of amiodarone treatment. However, Finerman et al. (21) 
studied patients after a mean of 11 weeks of amiodarone 
therapy and demonstrated electrophysiologic changes sim•
ilar to those we noted (3). Furthermore, recent data from 
Ferrick et al. (22) show that ventricular tachycardia induced 
after 2 weeks of amiodarone therapy in almost all patients 
can still be induced after 3 months of therapy. It is unrea•
sonable to keep patients hospitalized for months before re•
study at steady state amiodarone conditions, yet many pa•
tients will have recurrent arrhythmias or sudden death after 
hospital discharge, as noted in 14 (38%) of our 37 patients 
(Fig. 2). Thus, we believe it is important to develop methods 
to correctly classify those patients with inducible ventricular 
tachycardia during amiodarone therapy before hospital dis•
charge who are likely to have ventricular tachycardia or 
cardiac arrest after hospital discharge. In the present study 
we used discriminant analysis with multiple variables to 
predict clinical outcome and to arrive at this decision early 
in the patient's course of therapy. 
Our present approach to patients who have ventricular 
tachycardia induced during amiodarone therapy and appear 
to be at increased risk for recurrence of ventricular arrhyth•
mias during follow-up is to modify their drug therapy or 
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choose alternative forms of therapy, such as surgery. Further 
investigations at other medical centers are needed to deter•
mine whether the proposed discriminant function can be 
used to predict clinical outcome of patients treated with 
amiodarone. 
References 
I. Mason 1W, Winkle RA. Accuracy of the ventricular tachycardia•
induction study for predicting long-term efficacy and inefficacy of 
antiarrhythmic drugs. N Engl1 Med 1980;303:1073-7. 
2. NaccarelJi GV, Prystowsky EN, 1ackman WM, Heger 11, Rahilly GT, 
Zipes DP. Role of electrophysiologic testing in managing patients with 
ventricular tachycardia unrelated to coronary artery disease. Am 1 
Cardiol 1982;50;165-71. 
3. Heger 11, Prystowsky EN, 1ackman WM, et al. Amiodarone. Clinical 
efficacy and electrophysiology during long-term therapy for recurrent 
ventricular tachycardia or ventricular fibrillation. N Engl 1 Med 
1981;305:539-45. 
4. Waxman HL, Groh WC, Marchlinski FE, et al. Amiodarone for con•
trol of sustained ventricular tachyarrhythmia: clinical and electro•
physiologic effects in 51 patients. Am 1 Cardiol 1982;50:1066-74. 
5. Morady F, Scheinman M, Hess D. Amiodarone in the management 
of patients with malignant ventricular arrhythmias (abstr). Circulation 
1981;64(suppIIV):IV-36. 
6. Peter T, Hamer A, Weiss 0, Mandel W. Sudden death survivors: 
experience with long-term empiric therapy with amiodarone (abstr). 
Circulation 1981 ;64(suppl IV):IV -36. 
7. Nademanee K, Hendrickson 1, Kannan R, Singh BN. Antiarrhythmic 
efficacy and electrophysiologic actions of amiodarone in patients with 
life threatening ventricular arrhythmias: potent suppression of spon•
taneously occurring tachyarrhythmias versus inconsistent abolition of 
induced ventricular tachycardia. Am Heart 1 1982;103:950-9. 
8. Naccarelli GV, Prystowsky EN, 1ackman WM, Heger JJ, Rinken•
berger RL, Zipes DP. Repetitive ventricular response: prevalence and 
prognostic significance. Br Heart 11981;46:152-8. 
9. Snedecor GW, Cochran WG. Statistical Methods. Ames, IA: Iowa 
State University Press, 1967:215-21. 
NACCARELLI ET AL. 821 
ELECTROPHYSIOLOGIC RISK FACTORS WITH AMIODARONE 
10. Nie NH, Hull CH, 1enkins JG, Steinbrenner K, Bent DH. Statistical 
Packages for the Social Sciences. New York: McGraw-Hill, 
1975:434-48. 
II. Cox DR. Regression models and life tables. 1 R Stat Soc (B) 
1972;34:187-202. 
12. Bazett HC. An analysis of the time relations of electrocardiograms. 
Heart 1920;7:353-70. 
13. Heger JJ, Prystowsky EN, Zipes DP. Clinical efficacy of amiodarone 
in treatment of recurrent ventricular tachycardia and ventricular fi•
brillation. Am Heart 1 1983;106:887-92. 
14. Horowitz LN, Spielman SR, Greenspan AM, Webb CR, Kay HR. 
Ventricular arrhythmias: use of e1ectrophysiologic studies. Am Heart 
J 1983;106:881-6. 
15. McGovern B, Garan H, Malacoff RF, et al. Long-term clinical out•
comes of ventricular tachycardia or fibrillation treated with amioda•
rone. Am J Cardiol 1984;53:1558-63. 
16. Horowitz LN, Josephson ME, Farshidi A, Spielman SR, Michaelson 
EL, Greenspan AM. Recurrent sustained ventricular tachycardia. 3. 
Role of the electrophysiologic study in selection of antiarrhythmic 
regimens. Circulation 1978;58:986-97. 
17. Mason JW, Winkle RA. Electrode-catheter arrhythmia induction in 
the selection and assessment of antiarrhythmic drug therapy for re•
current ventricular tachycardia. Circulation 1978;58:971-85. 
18. Wellens HJJ, Duren DR, Lie KI. Observations on mechanisms of 
ventricular tachycardia in man. Circulation 1976;54:237-44. 
19. Josephson ME, Horowitz LN, Farshidi A, Kastor JA. Recurrent 
sustained ventricular tachycardia. 1. Mechanisms. Circulation 
1978;57:431-40. 
20. Holt OW, Storey GCA. Amiodarone pharmacokinetics. In: Breithardt 
G, Loogen F, eds. New Aspects in the Medical Treatment of Tachy•
arrhythmias. Munich: Urban and Schwarzenberg, 1983:69-72. 
21. Finerman WB, Peter T, Mandel W1. Studies on the electrophysiologic 
effects of amiodarone in man (abstr). Circulation 1980;62(suppl III):III-
152. 
22. Ferrick K1, Reiffel1A, Bigger IT, Livelli FD, Gang ES, Glik1ich 11. 
Amiodarone therapy: time course of electrophysio10gic effects (abstr). 
Clin Res 1983;31:182. 
